AI is the topic on everyone's mind these days.
Every prospective customer asks about it. Every CRO has an AI story. Every capabilities deck seems to promise faster timelines, smarter risk detection, more efficient monitoring, better site support, and fewer manual tasks.
And to be clear, there is a lot of value in many of those applications. But a sizeable amount of the AI currently in use remains at the surface.
It summarizes. It drafts. It searches. It flags. It organizes. These are useful capabilities that can remove friction from clinical operations and improve delivery excellence when they are implemented thoughtfully.
The consequential questions begin when AI moves deeper into the work: protocol writing, eligibility interpretation, safety-signal review, risk assessment, monitoring strategy, medical writing, and other decisions that sit close to patient safety, scientific integrity, regulatory expectations, and trial execution.
How do we handle the handoff between technology and human judgment? Who reviews the output and with what expertise? What must be verified before it becomes part of an official trial document, operational decision, or regulatory-aligned process? Where is the line between an AI recommendation and a human decision? Who has the authority to override the system? What triggers that override? And can the organization demonstrate, after the fact, how the final decision was made?
The April 2026 FDA warning letter to Purolea is instructive. Among the agency's concerns was the use of AI-generated cGMP documentation that had not been adequately reviewed, verified, and cleared by accountable human quality leadership.
EMA has also been clear that AI used in clinical trials remains subject to GCP expectations, that AI used in medicinal-product documents should operate under close human supervision, and that sponsors remain accountable for ensuring models and data pipelines are fit for purpose.
The regulatory direction is becoming consistent. AI can support the work, but it does not inherit the accountability. The operational challenge is how an organization designs, documents, and governs the moment an AI output becomes a human decision. And this is where the AI conversation becomes an operations conversation.
A sponsor or CRO cannot scale agentic AI responsibly through use-case inventories alone. An operating model, with clear decision rights, defined review points, escalation pathways, traceability, performance measures, and accountable ownership is needed.
The real differentiator will be whether an organization has designed the handoff. In what moment does an AI-generated output becomes a human-owned decision. AI can produce an answer in seconds, but clinical organizations still need to determine whether that answer is accurate, appropriate, and defensible, and answer the final question. Who is accountable if it is not?
